Publicaciones en colaboración con investigadores/as de University of Texas Southwestern Medical Center (120)

2022

  1. A pre-specified analysis of the Dapagliflozin and Prevention of Adverse Outcomes in Chronic Kidney Disease (DAPA-CKD) randomized controlled trial on the incidence of abrupt declines in kidney function

    Kidney International, Vol. 101, Núm. 1, pp. 174-184

  2. Achieving pain control in early rheumatoid arthritis with baricitinib monotherapy or in combination with methotrexate versus methotrexate monotherapy

    RMD Open, Vol. 8, Núm. 1

  3. Acute onset movement disorders in diabetes mellitus: A clinical series of 59 patients

    European Journal of Neurology, Vol. 29, Núm. 8, pp. 2241-2248

  4. An open-label, dose-escalation study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of single doses of GSK2586881 in participants with pulmonary arterial hypertension

    Pulmonary Circulation, Vol. 12, Núm. 1

  5. Association of chest compression pause duration prior to E-CPR cannulation with cardiac arrest survival outcomes

    Resuscitation, Vol. 177, pp. 85-92

  6. Conditional survival and long-term efficacy with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma

    Cancer, Vol. 128, Núm. 11, pp. 2085-2097

  7. Early short course of neuromuscular blocking agents in patients with COVID-19 ARDS: a propensity score analysis

    Critical Care, Vol. 26, Núm. 1

  8. Editorial: New Advances in Cardiorenal Syndrome

    Frontiers in Cardiovascular Medicine

  9. ISARIC-COVID-19 dataset: A Prospective, Standardized, Global Dataset of Patients Hospitalized with COVID-19

    Scientific Data, Vol. 9, Núm. 1

  10. Performance of the American Heart Association/American College of Cardiology/Heart Rhythm Society versus European Society of Cardiology guideline criteria for hospital admission of patients with syncope

    Heart Rhythm, Vol. 19, Núm. 10, pp. 1712-1722

  11. Phase I/II study of the LAG-3 inhibitor ieramilimab (LAG525) ± anti-PD-1 spartalizumab (PDR001) in patients with advanced malignancies

    Journal for immunotherapy of cancer, Vol. 10, Núm. 2